- Home
- ACAD vs RVLV Comparison
ACAD vs RVLV Comparison
Compare ACAD & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- RVLV
- Stock Information
- Founded
- ACAD 1993
- RVLV 2003
- Country
- ACAD United States
- RVLV United States
- Employees
- ACAD N/A
- RVLV N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- RVLV Catalog/Specialty Distribution
- Sector
- ACAD Health Care
- RVLV Consumer Discretionary
- Exchange
- ACAD Nasdaq
- RVLV Nasdaq
- Market Cap
- ACAD 3.8B
- RVLV N/A
- IPO Year
- ACAD 2004
- RVLV 2019
- Fundamental
- Price
- ACAD $20.95
- RVLV $21.37
- Analyst Decision
- ACAD Buy
- RVLV Buy
- Analyst Count
- ACAD 19
- RVLV 15
- Target Price
- ACAD $27.89
- RVLV $26.20
- AVG Volume (30 Days)
- ACAD 2.0M
- RVLV 1.2M
- Earning Date
- ACAD 08-05-2025
- RVLV 08-05-2025
- Dividend Yield
- ACAD N/A
- RVLV N/A
- EPS Growth
- ACAD N/A
- RVLV 106.68
- EPS
- ACAD 1.37
- RVLV 0.71
- Revenue
- ACAD $996,283,000.00
- RVLV $1,156,039,000.00
- Revenue This Year
- ACAD $13.39
- RVLV $7.71
- Revenue Next Year
- ACAD $10.59
- RVLV $7.64
- P/E Ratio
- ACAD $15.31
- RVLV $30.15
- Revenue Growth
- ACAD 22.42
- RVLV 9.09
- 52 Week Low
- ACAD $13.40
- RVLV $14.88
- 52 Week High
- ACAD $25.23
- RVLV $39.58
- Technical
- Relative Strength Index (RSI)
- ACAD 44.08
- RVLV 54.29
- Support Level
- ACAD $21.16
- RVLV $19.93
- Resistance Level
- ACAD $23.09
- RVLV $21.93
- Average True Range (ATR)
- ACAD 0.79
- RVLV 0.86
- MACD
- ACAD -0.34
- RVLV 0.05
- Stochastic Oscillator
- ACAD 4.58
- RVLV 71.67
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.